Air New Zealand is resuming daily return flights to Tokyo and Shanghai in response to strong growth in the Asian market.
Daily return services to Shanghai are being offered for the first time since Air NZ launched the route in 2006.
Airline deputy chief executive officer Norm Thompson says the Shanghai region is home to around 23 million people and the city is a perfect gateway for the rapidly growing Chinese market.
“China is now New Zealand’s second largest inbound tourist market, after Australia, having recently overtaken both North America and the UK."
And those to Tokyo have been resumed after three years, following the December capacity-boost on the route by more than 12% year-on-year.
And the return to a daily Auckland-Tokyo service after three years signals Air NZ’s commitment to the Japanese market, Mr Thompson says.
Capacity on the route was increased in December by more than 12%, year-on-year.
“The Japanese market is now showing signs of strong recovery after it was hit very hard by both the Christchurch earthquake and Japan tsunami in 2011 and we have continued to increase capacity on the Tokyo route in line with increased demand.”
This article is tagged with the following keywords. Find out more about MyNBR Tags
Most listened to
- Paul Brislen discusses the 'snake oil' sales tactics of SalesConcepts
- Fonterra chief executive Theo Spierings reveals his ambitious China plan
- UDC Finance chief executive Wayne Percival talks about the company's profit
- Hamish McNicol discusses the latest court stories
- Trilogy International CEO Angela Buglass reviews another bumper result
- Eroad CEO Steven Newman talks about his company's revenue increase
- What do the latest terrorism attacks in Mali and Israel mean? Nathan Smith discusses the latest foreign affairs news
- NZ Windfarms departing director Michael Stiassny speaks out after board exit
- James Mayo talks about SOS Hydration's growth plans after Snowball offer
- Michael Wood on whether he would run in Mt Roskill
- SAFE's Abi Izzard quizzed over protest of a caged hen operation at Pukekohe
- Nevil Gibson talks about Editor's Insight on the planned $US150 million merger between Pfizer and Allergan